159 related articles for article (PubMed ID: 38225669)
1. Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study.
Chu J; Tung L; Atallah I; Wei C; Cobleigh M; Rao R; Feinstein SB; Usha L; Banach K; Reiser J; Okwuosa TM
Cardiooncology; 2024 Jan; 10(1):3. PubMed ID: 38225669
[TBL] [Abstract][Full Text] [Related]
2. Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients.
Manshad AS; Ballout FA; Borgia JA; Reiser J; Okwuosa TM
Front Cardiovasc Med; 2021; 8():659524. PubMed ID: 35155590
[TBL] [Abstract][Full Text] [Related]
3. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
[TBL] [Abstract][Full Text] [Related]
4. Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.
Rasmussen LJH; Ladelund S; Haupt TH; Ellekilde GE; Eugen-Olsen J; Andersen O
Crit Care Med; 2018 Dec; 46(12):1961-1968. PubMed ID: 30247244
[TBL] [Abstract][Full Text] [Related]
5. Serum Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated with Low Left Ventricular Ejection Fraction and Elevated Plasma Brain-Type Natriuretic Peptide Level.
Fujita SI; Tanaka S; Maeda D; Morita H; Fujisaka T; Takeda Y; Ito T; Ishizaka N
PLoS One; 2017; 12(1):e0170546. PubMed ID: 28135310
[TBL] [Abstract][Full Text] [Related]
6. Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Drechsler C; Hayek SS; Wei C; Sever S; Genser B; Krane V; Meinitzer A; März W; Wanner C; Reiser J
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1265-1273. PubMed ID: 28495863
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
8. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.
Haugaard SB; Andersen O; Hansen TW; Eugen-Olsen J; Linneberg A; Madsbad S; Olsen MH; Jørgensen T; Borch-Johnsen K; Jeppesen J
Diabet Med; 2012 Apr; 29(4):479-87. PubMed ID: 22050462
[TBL] [Abstract][Full Text] [Related]
9. Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study.
Nusshag C; Rupp C; Schmitt F; Krautkrämer E; Speer C; Kälble F; Tamulyte S; Bruckner T; Zeier M; Reiser J; Weigand MA; Uhle F; Merle U; Morath C; Brenner T
Crit Care Med; 2019 Dec; 47(12):e999-e1007. PubMed ID: 31584458
[TBL] [Abstract][Full Text] [Related]
10. Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE).
Chalkias A; Laou E; Kolonia K; Ragias D; Angelopoulou Z; Mitsiouli E; Kallemose T; Smith-Hansen L; Eugen-Olsen J; Arnaoutoglou E
Surgery; 2022 Jun; 171(6):1619-1625. PubMed ID: 34736789
[TBL] [Abstract][Full Text] [Related]
11. A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor and Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome.
Sharma A; Ray S; Mamidipalli R; Kakar A; Chugh P; Jain R; Ghalaut MS; Choudhury S
Indian J Crit Care Med; 2020 Apr; 24(4):245-251. PubMed ID: 32565634
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A
Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985
[No Abstract] [Full Text] [Related]
13. Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
Kruger R; Rasmussen LM; Argraves WS; Eugen-Olsen J; Nielsen OW; Blyme A; Willenheimer R; Wachtell K; Olsen MH
PLoS One; 2014; 9(7):e101522. PubMed ID: 25014213
[TBL] [Abstract][Full Text] [Related]
14. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
Borné Y; Persson M; Melander O; Smith JG; Engström G
Eur J Heart Fail; 2014 Apr; 16(4):377-83. PubMed ID: 24464777
[TBL] [Abstract][Full Text] [Related]
15. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women.
Wlazeł RN; Guligowska A; Chrząstek Z; Kostka T; Jegier A; Szadkowska I
J Clin Med; 2023 May; 12(9):. PubMed ID: 37176730
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
Schuettfort VM; Pradere B; D'Andrea D; Grossmann NC; Quhal F; Mostafaei H; Laukhtina E; Mori K; Rink M; Karakiewicz PI; Motlagh RS; Katayama S; Lotan Y; Scherr D; Abufaraj M; Fajkovica H; Compérat E; Enikeev D; Shariat SF
J Urol; 2021 Nov; 206(5):1122-1131. PubMed ID: 34181469
[TBL] [Abstract][Full Text] [Related]
17. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
[TBL] [Abstract][Full Text] [Related]
18. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
[TBL] [Abstract][Full Text] [Related]
20. Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study.
van den Berg VJ; Bouwens E; Umans VAWM; de Maat M; Manintveld OC; Caliskan K; Constantinescu AA; Mouthaan H; Cornel JH; Baart S; Akkerhuis KM; Boersma E; Kardys I
Thromb Haemost; 2019 Dec; 119(12):1947-1955. PubMed ID: 31659734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
